A5023230423- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Neutropenia and Cancer Infections
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Gut microbiota and health
- Immune Cell Function and Interaction
- Endometrial and Cervical Cancer Treatments
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- Sarcoma Diagnosis and Treatment
- CAR-T cell therapy research
- Glioma Diagnosis and Treatment
- Chemotherapy-related skin toxicity
- Immunotherapy and Immune Responses
- Hematopoietic Stem Cell Transplantation
- Cancer Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Brain Metastases and Treatment
- Head and Neck Cancer Studies
Hospital Clínico Universitario Lozano Blesa
1995-2025
Instituto de Investigación Sanitaria Aragón
2016-2024
Spanish Ovarian Cancer Research Group
2023
Hospital Obispo Polanco
2004-2013
Hospital Arnau de Vilanova
2004-2009
Hospital Juan Ramón Jiménez
2007
Hospital General San Jorge
2004-2007
Universidad de Zaragoza
2007
Hospital Universitario Príncipe de Asturias
2006
Hospital Virgen de la Salud
2004-2006
PURPOSE Selinexor inhibits exportin-1 (XPO1) resulting in nuclear accumulation of tumor suppressor proteins including p53 and has clinical activity endometrial cancer (EC). The primary end point was to assess progression-free survival (PFS) with once-weekly oral selinexor patients advanced or recurrent EC. PATIENTS AND METHODS ENGOT-EN5/GOG-3055/SIENDO a randomized, prospective, multicenter, double-blind, placebo-controlled, phase III study at 107 sites 10 countries. Patients 18 years older...
PURPOSE EXONERATE (EXOsome and cell-free micro-RNAs of anti-EGFR ResistAnce) was an open-label, biomarker interventional study designed to develop, test, validate a liquid biopsy predictive progression-free survival (PFS), overall (OS), objective response rate (ORR) for first-line EGFR inhibitors in metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Patients with newly diagnosed RAS-WT, chemotherapy-naïve mCRC, both right- left-sided, were enrolled 2-nationwide trials receive...
Granulocyte colony-stimulating factors (G-CSFs) have been shown to help prevent febrile neutropenia in certain subgroups of cancer patients undergoing chemotherapy, but their role treating is controversial. The purpose our study was evaluate-in a prospective multicenter randomized clinical trial-the efficacy adding G-CSF broad-spectrum antibiotic treatment with solid tumors and high-risk neutropenia.A total 210 treated conventional-dose chemotherapy who presented fever grade IV were...
To determine the tolerability of capecitabine in elderly patients with advanced colorectal cancer (CRC).Fifty-one CRC who were >/= 70 years and considered ineligible for combination chemotherapy received oral 1,250 mg/m(2) twice daily on days 1 to 14 every 3 weeks. Patients a creatinine clearance 30 50 mL/min dose 950 daily.A total 248 cycles administered (median, five cycles; range, one eight cycles). The overall response rate was 24% (95% CI, 15% 41%), including two complete responses (CR;...
The purpose of this phase II trial was to determine the efficacy and safety XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in elderly patients with metastatic colorectal cancer (MCRC). A total 50 MCRC aged ⩾70 years received oxaliplatin 130 mg m−2 on day 1 followed by oral capecitabine 1000 twice daily days 1–14 every 3 weeks. Patients creatinine clearance 30–50 ml min−1 a reduced dose (750 daily). By intent-to-treat analysis, overall response rate 36% (95% CI, 28–49%), three...
To study the impact of transarterial Yttrium-90 radioembolization (TARE) in combination with second-line systemic chemotherapy for colorectal liver metastases (CLM).In this international, multicenter, open-label phase III trial, patients CLM who progressed on oxaliplatin- or irinotecan-based first-line therapy were randomly assigned 1:1 to receive without TARE. The two primary end points progression-free survival (PFS) and hepatic PFS (hPFS), assessed by blinded independent central review....
(1) Despite the effectiveness of immune checkpoint inhibitors (ICIs) in lung cancer, there is a lack knowledge about predictive biomarkers. The objective our study to analyze different subsets T-lymphocytes and natural killer (NK) cells as biomarkers cohort patients with nonsmall cell cancer (NSCLC) treated ICI. (2) This an observational, prospective 55 NSCLC A total 43 T NK are analyzed peripheral blood, including main markers exhaustion, differentiation, memory, activation, inhibition. (3)...
<div>AbstractPurpose:<p>The EXOsome and cell-free miRNAs of anti-EGFR ResistAnce (EXONERATE) study was an open-label, biomarker interventional designed to develop, test, validate a liquid biopsy predictive progression-free survival (PFS), overall (OS), objective response rate (ORR) for first-line EGFR inhibitors in metastatic colorectal cancer (mCRC).</p>Patients Methods:<p>Patients with newly diagnosed RAS wild-type, chemotherapy-naïve mCRC, both right- left-sided,...
<p>Supplementary figures</p>
<p>Supplementary methods and data</p>
Immune checkpoint inhibitors have been proposed as the standard treatment for different stages of non-small-cell lung cancer in multiple indications. Not all patients benefit from these treatments, however, and certain develop immune-related adverse events. Although search predictors response to drugs is a major field research, issues yet be resolved. It has postulated that microbiota could play relevant role conditioning treatments; human factor intestinal permeability also needs considered...
Cervical cancer (CC) is the fourth most common in women worldwide, strongly linked to high-risk human papilloma virus infection. In high-income countries, screening programs have dramatically decreased incidence of CC; however, lack accessibility them developing countries makes CC an important cause mortality. Clinical stage relevant prognostic factor CC. The new FIGO staging system published 2018 more accurate than previous one since it takes into account lymph node status. early stages,...
To identify characteristics associated with long-term progression-free survival (≥2 years) in patients advanced ovarian cancer treated niraparib first-line maintenance therapy the phase III PRIMA/ENGOT-OV26/GOG-3012 study. In this post hoc analysis of PRIMA, randomized to were grouped based on investigator-assessed (progressive disease/censoring <2 years or ≥2 after randomization). Variables assessed for predictive value Eastern Cooperative Oncology Group performance status, International...
<i>Background:</i> We gathered data from multiple institutions on the cetuximab regimen of patients with metastatic colorectal cancer. <i>Methods:</i> 126 19 centers were included July 2006 to 2007 in this prospective non-controlled study. Irinotecan-refractory cancer Karnofsky ≧70 received 500 mg/m<sup>2</sup> every 2 weeks (q2w) combination irinotecan 180 q2w until disease progression or unacceptable toxicity. The primary endpoint was progression-free...
Abstract Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Access Programme (RAP) was designed to provide early access rucaparib the above-mentioned indication, well patients with BRCA -mutated Pt-S or platinum-resistant (Pt-R) OC and no therapeutic alternatives. Methods: In this observational, retrospective study we analysed efficacy safety of within RAP Spain. Hospitals...
Peripheral neuropathy (PN) is the main side effect with cycles of paclitaxel at standard does (175 mg/m2 for 21 days). Administration a single high-dose (HDP) novel approach treatment cancer. We have prospectively measured neurotoxicity induced by HDP during phase I trial. Nineteen patients were treated escalating doses 24-hour infusion. In our study, PN was moderate, reversible, and not dose limiting. Severe seen in who had received previous neurotoxic chemotherapy, caution on...